Company Overview - Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative medicines to combat serious diseases [3] - The company has a broad and deep pipeline focused on treating cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [3] - Amgen has been recognized as one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes in 2024 [4] Upcoming Events - Amgen will present at Citi's 2025 Virtual Oncology Leadership Summit on February 19, 2025, at 3:00 p.m. ET [1] - Jean-Charles Soria, senior vice president of oncology within global development at Amgen, will be the presenter at the conference [1] - The webcast will be available for media, investors, and the general public, and will be archived for at least 90 days after the event [2]

Core Viewpoint - Investing in underperforming biotech stocks like CRISPR Therapeutics, Amgen, and Regeneron may present recovery opportunities despite their recent market losses [1][2]. Group 1: CRISPR Therapeutics - CRISPR Therapeutics specializes in gene editing and has developed Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia, but is currently not generating significant revenue [3][4]. - The company is unprofitable, leading to skepticism about its prospects, yet Casgevy has substantial potential, especially in the Middle East with an estimated patient population of at least 58,000 [4][6]. - The FDA granted RMAT designation to CRISPR's CTX112 for B-cell malignancies, indicating promising early data and high unmet needs, which could enhance its market position [6][7]. Group 2: Amgen - Amgen's stock declined after phase 2 data for its weight loss candidate, MariTide, but the company remains a strong long-term investment due to its diverse product lineup, including Tepezza for thyroid eye disease [8][9]. - The company has over 50 ongoing clinical trials, indicating a robust pipeline for future growth, and has increased its dividend payouts by 201% over the past decade, currently offering a yield of about 3.3% [10][11]. - Despite facing challenges like patent cliffs, Amgen's strong underlying business and innovative capabilities position it well for long-term success [11]. Group 3: Regeneron Pharmaceuticals - Regeneron relies on Dupixent and Eylea for revenue growth, but Eylea faces competition from Roche's Vabysmo and Amgen's Pavblu, creating uncertainty in its medium-term prospects [12][13]. - Dupixent has gained a new indication for chronic obstructive pulmonary disease, expected to add several billion dollars in annual revenue, contributing to a total revenue of $3.79 billion, a 10% increase year-over-year [14]. - Regeneron is expanding its oncology business with Libtayo and has numerous clinical trials underway, aiming to offset potential revenue losses from Eylea through innovation [16].

Core Points - Amgen will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference on February 12, 2025, at 11:20 a.m. ET [1] - The presentation will be led by Narimon Honarpour, senior vice president of global development at Amgen [1] - The webcast will be available for media, investors, and the general public, and will be archived for at least 90 days [2] Company Overview - Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative medicines for various diseases [3] - The company has a strong pipeline focused on treating cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [3] - Amgen has been recognized as one of the "World's Most Innovative Companies" and "America's Best Large Employers" in 2024 [4] - It is part of the Dow Jones Industrial Average and the Nasdaq-100 Index, highlighting its market significance [4]

Core Insights - Amgen is a leading player in the biotechnology market, benefiting from competitive advantages such as scale, R&D capabilities, manufacturing efficiency, and distribution networks [1] - The stock price of Amgen has increased due to improved results following the acquisition of Horizon Therapeutics, with rising margins and a strong pipeline of products [1] - Amgen is recognized as a Dividend Contender, indicating a commitment to dividend growth [1] Company Overview - Amgen's competitive advantages include significant scale, robust research and development, efficient manufacturing processes, and effective distribution channels [1] - The acquisition of Horizon Therapeutics has positively impacted Amgen's financial performance, contributing to stock price appreciation and improved margins [1] - The company maintains a strong product pipeline, which is crucial for future growth and sustainability [1] Investment Perspective - The focus on dividend growth investing aligns with Amgen's status as a Dividend Contender, appealing to long-term investors seeking sustainable income [1] - The biotechnology sector, particularly companies like Amgen, presents opportunities for capital appreciation alongside dividend growth [1]

Group 1 - The marketplace channel Haggerston BioHealth offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to investment bank-grade financial models and research [1] - The group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies [2]

Core Insights - Amgen Inc. reported strong earnings for Q4, surpassing analyst expectations for both earnings and revenue [1] - The company provided 2025 guidance that aligns with analyst expectations, indicating stability in future performance [1] Financial Performance - Amgen's Q4 earnings exceeded analyst forecasts, showcasing robust financial health [1] - Revenue figures were also above expectations, reflecting strong operational performance [1] Future Outlook - The 2025 guidance initiated by Amgen is generally in line with what analysts anticipated, suggesting confidence in continued growth [1]

Core Insights - Amgen Inc reported fourth-quarter sales of $9.10 billion, an 11% increase year-over-year, surpassing the consensus estimate of $8.9 billion [1] - The company achieved adjusted EPS of $5.31, exceeding the consensus of $5.08, despite the FDA placing a clinical hold on its Phase 1 study of AMG 513 for obesity [2] - Amgen anticipates fiscal year 2025 revenue between $34.3 billion and $35.7 billion, compared to a consensus of $34.5 billion, with adjusted EPS expected to be between $20 and $21.20 [3] Sales Performance - Product sales grew by 11%, primarily due to a 14% increase in volume; excluding sales from the Horizon Therapeutics acquisition, product sales increased by 10% with a 15% volume growth [6] - Ten products experienced at least double-digit sales growth in the fourth quarter, including Repatha, Blincyto, Tezspire, Evenity, and Tavneos [6] - Sales from rare disease products amounted to $1.2 billion, driven by early-in-lifecycle medicines such as Tepezza, Krystexxa, Uplinza, and Tavneos [6] Analyst Perspectives - Analysts remain positive about Amgen's performance, particularly regarding the value of MariTide in obesity and diabetes, along with upcoming approvals for other treatments [4] - The 2025 outlook aligns with expectations, highlighting ongoing investments in late-stage drugs, particularly MariTide and olpasiran [4] - Continued growth of key assets, including Repatha, Tezspire, Evenity, Blincyto, and Imdelltra, is expected to offset challenges from biosimilar launches, contributing to top-line growth [5] Stock Performance - Following the earnings report, AMGN stock rose by 5.41%, reaching $304.65 [5]

Amgen (AMGN) reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 13% year over year as higher revenues were partially offset by higher operating costs.Total revenues of $9.1 billion also beat the Zacks Consensus Estimate of $8.9 billion. Total revenues rose 11% year over year.Total product revenues increased 11% from the year-ago quarter to $8.72 billion as volume growth was partially offset by continued price declines. ...

Q4 '24 Earnings Call February 4, 2025 This presentation includes GAAP and non-GAAP financial measures. In accordance with the requirements of SEC Regulation G, reconciliations between these two measures, if these slides are in hard copy, accompany the hard copy presentation or, if these slides are delivered electronically, are available on the Company's website at www.amgen.com within the Investors section. Provided February 4, 2025, as part of an oral presentation and is qualified by such, contains forward ...

Amgen (AMGN) reported $9.09 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.9%. EPS of $5.31 for the same period compares to $4.71 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $8.86 billion, representing a surprise of +2.54%. The company delivered an EPS surprise of +5.57%, with the consensus EPS estimate being $5.03.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...